Peripheral mobilization of hematopoietic stem cells

Peripheral mobilization of hematopoietic stem cells is a therapeutic procedural indication rather than an intrinsic pathology or disease state

It refers to the pharmacologically induced egress of CD34-positive hematopoietic stem and progenitor cells from the bone marrow niche into the circulating peripheral vasculature This intervention affects the hematopoietic and vascular systems in patients with hematologic malignancies—such as multiple myeloma or non-Hodgkin lymphoma—as well as healthy allogeneic donors preparing for hematopoietic cell transplantation Pathophysiologically, the process disrupts key microenvironmental retention mech...

It refers to the pharmacologically induced egress of CD34-positive hematopoietic stem and progenitor cells from the bone marrow niche into the circulating peripheral vasculature Pathophysiologically, the process disrupts key microenvironmental retention mechanisms, such as the CXCR4 chemokine receptor interaction with stromal-derived CXCL12 and adhesion molecule anchoring, enabling the collection of sufficient graft cell yields via leukapheresis to ensure subsequent hematologic reconstitution

It refers to the pharmacologically induced egress of CD34-positive hematopoietic stem and progenitor cells from the bone marrow niche into the circulating peripheral vasculature Pathophysiologically, the process disrupts key microenvironmental retention mechanisms, such as the CXCR4 chemokine receptor interaction with stromal-derived CXCL12 and adhesion molecule anchoring, enabling the collection of sufficient graft cell yields via leukapheresis to ensure subsequent hematologic reconstitution

This intervention affects the hematopoietic and vascular systems in patients with hematologic malignancies—such as multiple myeloma or non-Hodgkin lymphoma—as well as healthy allogeneic donors preparing for hematopoietic cell transplantation

This intervention affects the hematopoietic and vascular systems in patients with hematologic malignancies—such as multiple myeloma or non-Hodgkin lymphoma—as well as healthy allogeneic donors preparing for hematopoietic cell transplantation

Pathophysiologically, the process disrupts key microenvironmental retention mechanisms, such as the CXCR4 chemokine receptor interaction with stromal-derived CXCL12 and adhesion molecule anchoring, enabling the collection of sufficient graft cell yields via leukapheresis to ensure subsequent hematologic reconstitution